Krystal Biotech, Inc. (NASDAQ: KRYS) is a burgeoning player in the biotechnology sector, making significant strides in the genetic medicine landscape. With a market cap of $8.06 billion, this Pittsburgh-based company is captivating investor interest through its innovative treatments for diseases with high unmet medical needs.

Krystal Biotech has made headlines with its flagship product, VYJUVEK (B-VEC), indicated for dystrophic epidermolysis bullosa (DEB), a genetic disorder with few effective treatments. This product not only highlights the company’s commitment to pioneering therapies but also positions it well in a niche market segment ripe for growth.

Investors eyeing KRYS should note the company’s robust revenue growth at…